SCHEMBL19002552

SCHEMBL19002552

CCCc1cc(C(=O)OC)sc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
HPGD P15428 3/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CNR1 P21554 3/20 0.42
RAB9A P51151 3/20 0.41
CSNK2A2 P19784 1/20 0.41
KDR P35968 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
KIFC1 Q9BW19 2/20 0.39
KDM4E B2RXH2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19049035 0.88 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2HTTHPGDMAPK1
SCHEMBL16755986 0.84 DAO (0.55) ALDH1A1SMN1; SMN2HTTCNR1KIFC1
SCHEMBL16639425 0.82 HPGD (0.42) ALDH1A1SMN1; SMN2HPGDMAPK1TSHR
SCHEMBL18997394 0.80 HPGD (0.43) ALDH1A1SMN1; SMN2HTTHPGDMAPK1
SCHEMBL21740768 0.80 HPGD (0.47) ALDH1A1SMN1; SMN2HTTHPGDMAPK1
SCHEMBL21169209 0.79 KDM4E (0.40) ALDH1A1SMN1; SMN2HTTHPGDMAPK1
SCHEMBL1529879 0.75 HPGD (0.37) ALDH1A1SMN1; SMN2HPGDMAPK1TSHR
SCHEMBL17398200 0.75 HSP90AA1 (0.46) ALDH1A1SMN1; SMN2HTTHPGDL3MBTL1
SCHEMBL9925990 0.74 KDM4E (0.67) ALDH1A1SMN1; SMN2HPGDMAPK1TSHR
SCHEMBL18420119 0.74 HPGD (0.46) ALDH1A1SMN1; SMN2HTTHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885SMN1; SMN2 4331/4885HTT 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.